Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: An individual patient data meta-analysis

Petroff, David and Blank, Valentin and Newsome, Philip N. and Shalimar, Shalimar and Voican, Cosmin Sebastian and Thiele, Maja and de Ledinghen, Victor and Baumeler, Stephan and Chan, Wah Kheong and Perlemuter, Gabriel and Cardoso, Ana-Carolina and Aggarwal, Sandeep and Sasso, Magali and Eddowes, Peter J. and Allison, Michael and Tsochatzis, Emmanuel and Anstee, Quentin M. and Sheridan, David and Cobbold, Jeremy F. and Naveau, Sylvie and Lupsor-Platon, Monica and Mueller, Sebastian and Krag, Aleksander and Irles-Depe, Marie and Semela, David and Wong, Grace Lai-Hung and Wong, Vincent Wai-Sun and Villela-Nogueira, Cristiane A. and Garg, Harshit and Chazouilleres, Olivier and Wiegand, Johannes and Karlas, Thomas Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: An individual patient data meta-analysis. Lancet Gastroenterology & Hepatology, 6 (3). pp. 185-198. ISSN 2468-1253, DOI

Full text not available from this repository.


Background Diagnostic tools for liver disease can now include estimation of the grade of hepatic steatosis (S0 to S3). Controlled attenuation parameter (CAP) is a non-invasive method for assessing hepatic steatosis that has become available for patients who are obese (FibroScan XL probe), but a consensus has not yet been reached regarding cutoffs and its diagnostic performance. We aimed to assess diagnostic properties and identify relevant covariates with use of an individual patient data meta-analysis. Methods We did an individual patient data meta-analysis, in which we searched PubMed and Web of Science for studies published from database inception until April 30, 2019. Studies reporting original biopsy-controlled data of CAP for non-invasive grading of steatosis were eligible. Probe recommendation was based on automated selection, manual assessment of skin-to-liver-capsule distance, and a body-mass index (BMI) criterion. Receiver operating characteristic methods and mixed models were used to assess diagnostic properties and covariates. Patients with non-alcoholic fatty liver disease (NAFLD) were analysed separately because they are the predominant patient group when using the XL probe. This study is registered with PROSPERO, CRD42018099284. Findings 16 studies reported histology-controlled CAP including the XL probe, and individual data from 13 papers and 2346 patients were included. Patients with a mean age of 46.5 years (SD 14.5) were recruited from 20 centres in nine countries. 2283 patients had data for BMI; 673 (29%) were normal weight (BMI <25 kg/m(2)), 530 (23%) were overweight (BMI >= 25 to <30 kg/m(2)), and 1080 (47%) were obese (BMI >= 30 kg/m(2)). 1277 (54%) patients had NAFLD, 474 (20%) had viral hepatitis, 285 (12%) had alcohol-associated liver disease, and 310 (13%) had other liver disease aetiologies. The XL probe was recommended in 1050 patients, 930 (89%) of whom had NAFLD; among the patients with NAFLD, the areas under the curve were 0.819 (95% CI 0.769-0.869) for S0 versus S1 to S3 and 0.754 (0.720-0.787) for S0 to S1 versus S2 to S3. CAP values were independently affected by aetiology, diabetes, BMI, aspartate aminotransferase, and sex. Optimal cutoffs differed substantially across aetiologies. Risk of bias according to QUADAS-2 was low. Interpretation CAP cutoffs varied according to cause, and can effectively recognise significant steatosis in patients with viral hepatitis. CAP cannot grade steatosis in patients with NAFLD adequately, but its value in a NAFLD screening setting needs to be studied, ideally with methods beyond the traditional histological reference standard.

Item Type: Article
Funders: Federal Ministry of Education & Research (BMBF)
Subjects: R Medicine > R Medicine (General)
Divisions: Faculty of Medicine > Medicine Department
Depositing User: Ms Zaharah Ramly
Date Deposited: 07 Jul 2022 01:46
Last Modified: 07 Jul 2022 01:46

Actions (login required)

View Item View Item